EKF launches high performance quantitative COVID-SeroKlir antibody test kit

EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals. Unlike other antibody tests, the Kantaro COVID-SeroKlir SARS-CoV-2 IgG antibody test kit determines both the presence and specific quantities of human IgG antibodies to the SARS-CoV-2 virus. This enables a broad range of COVID-19 applications, such as delivering vital knowledge for advancing the understanding of protective immunity, assessing vaccine response and accelerating therapeutic treatments.

EKF launches high performance quantitative COVID-SeroKlir antibody test kit
The COVID-SeroKlir SARS-CoV-2 IgG antibody test kit enables precise quantitative detection

The high performance quantitative COVID-SeroKlir kit has received FDA Emergency Use Authorization (EUA) and is CE marked. It has demonstrated 98.8% sensitivity and 99.6% specificity for detecting SARS-CoV-2 specific IgG antibodies against two SARS-CoV-2 virus antigens, the full-length spike protein and its receptor-binding domain (RBD). This confirmed accuracy means false positives and false negatives are minimized.

Being a two-step enzyme-linked immunosorbent assay (ELISA), ensures COVID-SeroKlir’s accuracy. The ELISA’s initial plate screens for RBD positive or negative samples, whilst the second plate provides a quantitative result of the antibody titre/concentration for the full-length spike protein. As the kit uses standard methods and equipment, it is easily operated without need for scaled equipment or special environments and contains components to test 630 patient samples.

The best-in-class serologic COVID-19 assay is based on technology developed by clinicians at the Icahn School of Medicine at Mount Sinai Health System in New York in partnership with RenalytixAI, a spinout company from EKF Diagnostics. Here, COVID-SeroKlir has been validated on a highly diverse cohort of more than 75,000 patients, including over 30,000 who were diagnosed with COVID-19; this is more than any other COVID-19 test. In addition, the test has been independently verified by peer reviewed journals, including Nature and Science, as well as the U.S. National Institutes of Health (NIH).

The Mount Sinai study also demonstrated that over 90% of infected individuals with mild-to-moderate COVID-19 experience robust IgG antibody responses against the viral spike protein. In addition, these COVID-19 neutralizing antibody levels were confirmed to be relatively stable during the first five months after infection.

Explaining the value of knowing the precise levels of SARS-CoV-2 IgG antibodies, Julian Baines, CEO of EKF, said, “Quantitative IgG antibody testing can provide important support for determining public health strategies, informing healthcare decision making, and verifying the effectiveness of vaccines as they become available. It is also an essential component of a general health check to determine past COVID-19 infections. This is because COVID-19 has been linked with an increased risk of potentially life-threatening complications, including lung, kidney, and cardiovascular disease.”

EKF holds exclusive rights to market and distribute the Kantaro COVID-SeroKlir kit in the UK and Germany, and non-exclusive rights in the rest of Europe.

With the capacity to manufacture up to 10 million tests per month, EKF is well placed to drive rapid availability of COVID-SeroKlir kits to a broad range of laboratories for immediate operation without needing specialized testing equipment.”

Julian Baines, CEO, EKF

Journal references:
  1. Amant, F. et al. (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature Medicine. doi.org/10.1038/s41591-020-0913-5
  2. Wajnberg, A., et al. (2020). Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. doi.org/10.1126/science.abd7728


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    EKF Diagnostics. (2020, December 10). EKF launches high performance quantitative COVID-SeroKlir antibody test kit. News-Medical. Retrieved on November 27, 2021 from https://www.news-medical.net/news/20201210/EKF-launches-high-performance-quantitative-COVID-SeroKlir-antibody-test-kit.aspx.

  • MLA

    EKF Diagnostics. "EKF launches high performance quantitative COVID-SeroKlir antibody test kit". News-Medical. 27 November 2021. <https://www.news-medical.net/news/20201210/EKF-launches-high-performance-quantitative-COVID-SeroKlir-antibody-test-kit.aspx>.

  • Chicago

    EKF Diagnostics. "EKF launches high performance quantitative COVID-SeroKlir antibody test kit". News-Medical. https://www.news-medical.net/news/20201210/EKF-launches-high-performance-quantitative-COVID-SeroKlir-antibody-test-kit.aspx. (accessed November 27, 2021).

  • Harvard

    EKF Diagnostics. 2020. EKF launches high performance quantitative COVID-SeroKlir antibody test kit. News-Medical, viewed 27 November 2021, https://www.news-medical.net/news/20201210/EKF-launches-high-performance-quantitative-COVID-SeroKlir-antibody-test-kit.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
EKF opens larger facility to increase production of key component for COVID-19 testing regime